TransMedics Group - TMDX Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TMDX shares.
View TMDX analyst ratings or view top-rated stocks.

7 analysts have issued 1-year price objectives for TransMedics Group's shares. Their TMDX share price forecasts range from $39.00 to $70.00. On average, they expect the company's share price to reach $53.29 in the next twelve months. This suggests that the stock has a possible downside of 19.4%.
View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts.

TransMedics Group's stock was trading at $61.72 at the beginning of the year. Since then, TMDX shares have increased by 7.1% and is now trading at $66.13.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our TMDX earnings forecast.

TransMedics Group, Inc. (NASDAQ:TMDX) issued its earnings results on Thursday, November, 3rd. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.15. The company had revenue of $25.68 million for the quarter, compared to the consensus estimate of $18.96 million. TransMedics Group had a negative trailing twelve-month return on equity of 46.03% and a negative net margin of 58.78%.

TransMedics Group issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $80.00 million-$85.00 million, compared to the consensus revenue estimate of $75.66 million.

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

TransMedics Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (1.87%), Baillie Gifford & Co. (0.79%), Peregrine Capital Management LLC (0.42%), Calamos Advisors LLC (0.19%), Park Avenue Securities LLC (0.04%) and Dupont Capital Management Corp (0.02%). Insiders that own company stock include Abrams Capital Management, LP, David Weill, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends.

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TMDX stock can currently be purchased for approximately $66.13.

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $2.11 billion and generates $30.26 million in revenue each year. The company earns $-44,220,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

The company employs 148 workers across the globe.

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.